Anthrax Clinical Trial
Official title:
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 31, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid. 2. Multiple organ dysfunction (MODS) in brain, heart, liver, kidney, coagulation or more than one organ failure. Exclusion Criteria: There are other conditions that affect short-term survival. |
Country | Name | City | State |
---|---|---|---|
China | Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Qin Ning |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mortality rates of severe anthrax | mortality rates of severe anthrax | 28 days and 90 days | |
Secondary | incidence of complications | To evaluate the incidence of respiratory, circulatory, neurological, digestive, coagulation and other complications of severe anthrax | in hospital | |
Secondary | Peripheral blood biomarkers associated with 28-day and 90-day mortality | Peripheral blood biomarkers associated with 28-day and 90-day mortality | 28 days and 90 days | |
Secondary | the improvement in 28-day and 90-day mortality with treatment for severe anthrax | the improvement in 28-day and 90-day mortality with treatment for severe anthrax | 28 days and 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00114621 -
Anthrax Vaccine Clinical Trials
|
Phase 1 | |
Recruiting |
NCT00050310 -
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
|
||
Completed |
NCT01453907 -
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
Completed |
NCT01491607 -
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
|
Phase 3 | |
Completed |
NCT03518125 -
BARDA Securing Anthrax Immunity For the Elderly
|
Phase 2 | |
Completed |
NCT04660201 -
Anthrax AV7909 Liquid vs Lyophilized
|
Phase 1 | |
Completed |
NCT04320485 -
Evaluation of the Clinical Specificity of the Active Anthrax Detectâ„¢ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
|
||
Completed |
NCT03877926 -
VELOCITY: An Anthrax Vaccine Clinical Study
|
Phase 3 | |
Completed |
NCT03498027 -
Febrile Whole Blood Specimen Collection and Testing
|
||
Terminated |
NCT00964834 -
Ph1 Study of Valortim and Doxycycline in Humans
|
Phase 1 | |
Completed |
NCT00063843 -
Anthrax-rPA: Safety, Tolerability, Immunogenicity
|
Phase 1 | |
Completed |
NCT01624532 -
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
|
Phase 2 | |
Completed |
NCT04148118 -
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
|
Phase 1 | |
Terminated |
NCT05672875 -
Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
|
||
Completed |
NCT01770743 -
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
|
Phase 2 | |
Completed |
NCT01867957 -
Efficacy and Safety of Anthrax Vaccine, GC1109
|
Phase 1 | |
Completed |
NCT00845650 -
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
|
Phase 1/Phase 2 | |
Completed |
NCT00031291 -
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
|
N/A | |
Not yet recruiting |
NCT03569514 -
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
|
||
Recruiting |
NCT05997264 -
Anthrax AV7909 Boost Evaluation Study
|
Phase 2 |